Neurology & Neurodegeneration
HMGCS2-dependent β-OHB/H3K9bhb ameliorates synaptic plasticity and cognition in Alzheimer's disease
This research reveals that upregulation of 3-hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2), a rate-limiting enzyme in β-hydroxybutyrate (β-OHB) synthesis, significantly improves cognitive function and synaptic plasticity in Alzheimer's disease (AD) models. The study found that both β-OHB and histone3-lysine9-β-hydroxybutyrylation (H3K9bhb) levels were reduced in AD brains, and their restoration via HMGCS2 upregulation or β-OHB replenishment enhanced NMDA receptor subunits, Syn1, and overall cognitive function. This highlights HMGCS2 as a critical molecular switch and suggests targeting HMGCS2 or β-OHB as a novel therapeutic strategy for AD treatment, offering a new epigenetic regulatory mechanism in AD.
Executive Impact
Leveraging these insights, OwnYourAI helps enterprises achieve measurable improvements in R&D and operational efficiency.
0
Improvement in Cognitive Function
0
Enhancement of Synaptic Plasticity
0
Faster Drug Target Identification
0
Reduction in Alzheimer's Disease Progression Markers
Deep Analysis & Enterprise Applications
Select a topic to dive deeper, then explore the specific findings from the research, rebuilt as interactive, enterprise-focused modules.
This category focuses on diseases affecting the nervous system, including Alzheimer's disease, and the mechanisms underlying neurodegeneration. Key areas include synaptic dysfunction, cognitive impairment, and the role of novel biomarkers and therapeutic targets.
83.14%
of H3K9bhb-positive cells co-localized with neurons, indicating its predominant role in neuronal function.
| Marker | 3xTg-AD Mice (Baseline) | 3xTg-AD with HMGCS2 Upregulation | 3xTg-AD with β-OHB Supplementation |
|---|---|---|---|
| Glun1 (NMDAR subunit) | Decreased | Increased | Increased |
| Glun2A (NMDAR subunit) | Decreased | Increased | Increased |
| Glun2B (NMDAR subunit) | Decreased | Increased | Increased |
| Syn1 (Synaptic Vesicle Protein) | Decreased | Increased | Increased |
| H3K9bhb Enrichment at Promoters | Reduced | Enhanced | Enhanced |
+20%
Increase in dendritic spine density observed with HMGCS2 overexpression, indicating enhanced synaptic stability.
Mechanism of Cognitive Improvement in AD
AD Pathology (Reduced β-OHB & H3K9bhb)
→
Impaired Synaptic Plasticity & Cognition
→
HMGCS2 Upregulation / β-OHB Supplementation
→
Increased H3K9bhb
→
Enhanced NMDA Receptor & Syn1 Expression
→
Restored Synaptic Integrity
→
Improved Cognitive Function
This section explores how gene expression is modulated without altering the underlying DNA sequence. It delves into histone modifications, such as β-hydroxybutyrylation, and their role in chromatin remodeling and gene activation, particularly in the context of disease pathogenesis.
HMGCS2: A Key Epigenetic Switch in AD
"HMGCS2 acts as a pivotal molecular switch, modulating both β-OHB levels and the epigenetic landscape, directly impacting neuronal health in AD."
Lead Researcher, OwnYourAI Analysis
The study identified HMGCS2 as a critical enzyme in β-OHB synthesis, directly influencing H3K9bhb levels.
Decreased HMGCS2 expression in AD patients and models leads to reduced β-OHB and H3K9bhb, impairing synaptic function.
Overexpression of HMGCS2 effectively restores β-OHB and H3K9bhb, ameliorating cognitive deficits and synaptic plasticity.
This category covers the biochemical pathways involved in metabolism, focusing on the production and utilization of key metabolites like β-hydroxybutyrate (β-OHB). It examines the enzymes involved in ketone body synthesis and their broader implications for cellular function and disease.
Ketone Body Synthesis Pathway & Epigenetic Link
Fatty Acid β-Oxidation
→
Acetoacetyl-CoA (AcAc-CoA)
→
Acetyl-CoA
→
HMGCS2 Condensation
→
3-Hydroxy-3-Methylglutaryl-CoA (HMG-CoA)
→
HMGCL Cleavage
→
Acetoacetate
→
BDH1 Catalysis
→
β-OHB Production
→
H3K9bhb Modification & Gene Expression
Calculate Your Potential ROI
See how OwnYourAI can translate scientific breakthroughs into tangible value for your organization. Adjust the parameters to estimate your potential savings and reclaimed hours.
Estimated Annual Savings
$0
Annual Hours Reclaimed
0
Your AI Implementation Roadmap
Our structured approach ensures seamless integration and maximum impact for your enterprise.
Phase 01: Discovery & Strategy
Deep dive into your R&D objectives, current workflows, and data infrastructure to tailor an AI strategy that aligns with your specific goals.
Phase 02: AI Model Development & Training
Leverage cutting-edge AI to build custom models, trained on both public research and your proprietary data, to identify novel insights and accelerate discovery.
Phase 03: Integration & Deployment
Seamlessly integrate AI solutions into your existing platforms, ensuring minimal disruption and maximum user adoption. We support various deployment environments.
Phase 04: Performance Monitoring & Optimization
Continuous monitoring of AI model performance, with ongoing optimization and updates to ensure sustained accuracy and relevance in a dynamic scientific landscape.
Ready to Transform Your Research?
Schedule a personalized consultation with our AI specialists to explore how OwnYourAI can unlock unprecedented value for your enterprise.
Ready to Get Started?
Book Your Free Consultation.
Let's Discuss Your AI Strategy!
Lets Discuss Your Needs
Select a Date
Sun
Mon
Tue
Wed
Thu
Fri
Sat